Idiopathic Pulmonary Fibrosis Clinical Trials in Philadelphia, Pennsylvania

4 studies are recruiting for idiopathic pulmonary fibrosis in Philadelphia, Pennsylvania right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment

   This study is open to adults who are at least 40 years old and have idiopathic pulmonary fibrosis (IPF). People can participate in the study if they have a forced vital capacity (FVC) greater than or equal to 45% of the predicted value and fibrosis of 20% or more confirmed by a high-resolution comp…

   Stage

   Phase 2

   Ages

   40 and older

   Site

   Temple University, Philadelphia, Pennsylvania

   Locations

   46 in total

   Run by

   Boehringer Ingelheim

   See if you can join NCT07036523 on ClinicalTrials.gov

2. Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis

   Idiopathic Pulmonary Fibrosis (IPF) is a rare, long-lasting lung disease that causes scarring of lung tissue, shortness of breath, and loss of lung function. IPF leads to significant loss of quality of life and shortened lifespan. This study is a platform study evaluating different types of treatme…

   Stage

   Phase 2

   Ages

   40 and older

   Site

   Jefferson Health Honickman Center /ID# 279127, Philadelphia, Pennsylvania

   Locations

   57 in total

   Run by

   AbbVie

   See if you can join NCT07230288 on ClinicalTrials.gov

3. Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)

   Ifetroban prevents and treats lung fibrosis due to multiple causes (bleomycin, genetic, radiation). The safety and efficacy of oral ifetroban will be assessed in patients with IPF.

   Stage

   Phase 2

   Ages

   40 and older

   Site

   Temple University Hospital, Philadelphia, Pennsylvania

   Locations

   20 in total

   Run by

   Cumberland Pharmaceuticals

   See if you can join NCT05571059 on ClinicalTrials.gov

4. A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

   This study is open to people with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). They can only take part if they have completed treatment in a previous study with a medicine called nerandomilast or BI 1015550. The goal of this study is to find out how well people with …

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University of Pennsylvania, Philadelphia, Pennsylvania

   Locations

   373 in total

   Run by

   Boehringer Ingelheim

   See if you can join NCT06238622 on ClinicalTrials.gov